Diethyl 2-propyl-1H-Imidazole-4,5-Dicarboxylatus CAS 144689-94-1 Puritas >99.0% (HPLC) Olmesartan Medoxomil Factory intermedium

Description:

Diethyl 2-propyl-1H-Imidazole-4,5-Dicarboxylate

CAS: 144689-94-1

Puritas: >99.0% (HPLC)

Aspectus: Pallida Yellow ad Off-Pulvis alba

Medius Olmesartan Medoxomil

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Descriptio:

Chemical Properties:

Nomen chemicum Diethyl 2-propyl-1H-Imidazole-4,5-Dicarboxylate
Synonyma Diethyl 2-PropylImidazoledicarbonate;2-Propyl-1H-Imidazole-4,5-Dicarboxylic Acidum Diethyl Ester;2-Propylimidazoledicarboxylic Acidum Diethyl Ester
CAS Number 144689-94-1
CATTUS Number RF-PI1872
Stock Status In Stock, Productio Ascendite ad Tons
Formulae hypotheticae C12H18N2O4
M. Pondus 254.29
Density 1.160±0.06 g/cm3
Brand Ruifu Chemical

Specifications:

Item Specifications
Aspectus Pallidus ad Off-White pulveris
Puritas / Analysis Methodus >99.0% (HPLC)
Liquescens punctum 83.0~88.0℃
Aqua Content (KF) <0.50%
Residere in Ignition <0.20%
Maximum Impuritas <0.50%
Totalis immunditias <1.00%
Proton NMR Spectrum Conformat ut Structure
Test Standard Enterprise Standard
Consuetudinem Medium Olmesartan Medoxomil (CAS: 144689-63-4);

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

1

FAQ:

Applicatio:

Diethyl 2-Propyl-1H-Imidazole-4,5-Dicarboxylatus (CAS: 144689-94-1) medium est in synthesi Olmesartanae Medoxomil (CAS: 144689-63-4).Medoxomil Olmesartan curatione sanguinis pressi (hypertension).Princeps sanguinem pressura submittendo adiuvat ne ictus, cordis impetus, et difficultates renis.Olmesartan pertinet ad genus medicamentorum quod angiotensin receptor blockers (ARBs).Olmesartan operatur venas laxando ut sanguis facilius fluat.Sola adhiberi potest vel coniunctio cum aliis agentibus antihypertensivis.US Food and Drug Administration (FDA) decrevit beneficia Benicar pergere ad praeponderare periculum potentiale cum adhibitis ad curationem aegrorum magno sanguinis pressione secundum pittacium medicamentorum.

Epistulam tuam hic scribe et mitte nobis